Skip to content
Search

Latest Stories

RPS England director Ravi Sharma resigns to take up top job at Luton & Dunstable University Hospital

The Royal Pharmaceutical Society (RPS) England director, Ravi Sharma, has resigned after four years on the job.

He will be leaving the RPS in October to join Luton and Dunstable University Hospital, part of the Bedfordshire Hospitals NHS Foundation Trust group, as head of pharmacy.


RPS will be commencing the recruitment of a new director for England shortly and in the interim Ravi will be working with Paul Bennett, the RPS CEO, to help in delivery of key objectives and in the appointment of his successor.

Paul commented: “Ravi has made a significant contribution to the organization during his time with us. His drive and enthusiasm for advancing the recognition of the role of the Society itself and of pharmacists and professional practice is probably best reflected by his desire to ensure a real focus on personalized medicines and his work on equality and diversity, workforce wellbeing, and most recently the development of a new vision for pharmacy in England.

"He has developed stronger relationships and collaborative working with Government, Department of Health and Social Care, NHS England, professional leadership bodies, organisations and patient groups over the years to support implementation of our policies and advocacy work.

“Ravi became a Fellow of the Society in 2022, in well-deserved recognition of his contribution to the profession and I know we can expect to see him remain close to the work of the RPS and a real advocate for the Society’s professional leadership role.

Ravi Sharma commented: "It’s been an honour and a privilege to lead the team in England at RPS on behalf of our members, and the wider profession.

“I want to pay tribute to the dedication of my colleagues who have been instrumental in supporting the profession through Covid-19, raising the profile of pharmacy with NHS leaders and politicians and bringing our strategy on inclusion and diversity to life.

“Our recent collaborative work on co-creating a vision for pharmacy in England will provide the profession with a blueprint for the future. This work will continue, I look forward to seeing it develop from my new vantage point within the NHS.

“Improving care for patients and the public through pharmacy remains my personal mission. I am hugely excited about the opportunity to work with the senior leadership team at Bedfordshire Hospitals NHS Foundation Trust. I am looking forward to putting theory into practice, working with the fantastic team who are delivering critical NHS hospital services.

“I’m very appreciative of the fantastic opportunities I’ve had at RPS and I am confident the organisation will continue to represent the best of pharmacy and professional leadership in the future.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less